AbbVie raises $10B in debt to fund acquisition of Apogee Therapeutics

{
  "signal_id": "f3112e5e-2921-4abb-9495-6d382068bc65",
  "signal_type": "sec-8k",
  "signal_subtype": "debtRefinancing",
  "detected_at": "2026-08-25T07:05:36.307+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "detail": "AbbVie completed a $10 billion senior notes offering to finance its acquisition of Apogee Therapeutics. This major M&A event signals significant upcoming spend on integration activities, including IT systems, financial reporting, and operational consolidation, creating opportunities for relevant service and technology vendors.",
    "metrics": {
      "timeframe": "immediate",
      "dollar_context": "Total aggregate principal from a senior notes offering to fund the acquisition of Apogee Therapeutics, Inc. and related fees.",
      "dollar_millions": 10000
    },
    "summary": "AbbVie raises $10B in debt to fund acquisition of Apogee Therapeutics",
    "excerpts": "On August 18, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028..., $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028..., $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030..., $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031..., $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033..., $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036..., $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038..., $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056... and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066...",
    "relevance": 0.9,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/tm2623337d1_8k.htm",
    "filing_date": "2026-08-18",
    "filing_year": 2026,
    "sales_relevance": "Capital available or pressure",
    "signal_category": "financial",
    "vendors_mentioned": [
      "U.S. Bank Trust Company, National Association",
      "Wachtell, Lipton, Rosen & Katz"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/f3112e5e-2921-4abb-9495-6d382068bc65 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'